ClinicalTrials.gg
CompletedNCT00783692GEMINI IIUpdated Jul 21, 2014Results posted

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

A Phase 3 interventional study of vedolizumab and Placebo in Crohn's Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 114 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-21.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,116
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
2nd of 39
1,116 · median 101
Started
2008
the only one that year
Phase 3
16 of 39
6 open now
Registered
3rd of 39
by date
Lead sponsor
4 of 39
Millennium Pharmaceuticals, Inc.

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 16 in phase 3, and was the 3rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.

Read the detailed description

Study C13007 comprised 2 randomized, double-blind, placebo-controlled studies conducted under 1 protocol which, operationally, consisted of 2 phases.

  • The Induction Phase, designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and clinical remission, and
  • The Maintenance Phase, designed to establish the efficacy and safety of vedolizumab for the maintenance of clinical response and clinical remission.

The 6-week Induction Phase contained 2 cohorts of participants: Cohort 1 participants were randomized and treated with double-blind study drug, and Cohort 2 participants were treated with open-label vedolizumab. The second cohort was enrolled to ensure that the sample size of Induction Phase responders randomized into the Maintenance Study provided sufficient power for the Maintenance Study primary efficacy analysis. These participants did not contribute to the efficacy analyses performed for the Induction Study. Participants in both cohorts were assessed for treatment response at Week 6.

In the Maintenance Phase vedolizumab-treated participants from both Cohort 1 and Cohort 2 who demonstrated a clinical response were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks (Q4W), vedolizumab administered every 8 weeks (Q8W), or placebo. Vedolizumab-treated participants who did not demonstrate response at Week 6 continued treatment with open-label vedolizumab, administered Q4W. Participants treated with double-blind placebo in the Induction Phase continued on double-blind placebo during the Maintenance Phase, regardless of treatment response during induction. The Maintenance Phase began at Week 6 and concluded with Week 52 assessments.

After the Week 52 assessments, participants may have been eligible to enroll in Study C13008 (NCT00790933; Long-term Safety Study) to receive open-label vedolizumab treatment. Participants who withdrew early (prior to Week 52) due to sustained nonresponse, disease worsening, or the need for rescue medications may have been eligible to enroll in Study C13008. Participants who did not enroll into Study C13008 were to complete a final on-study safety assessment at Week 66 (or Final Safety visit 16 weeks after the last dose) in the Maintenance Phase of Study C13007.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 80
  2. Diagnosis of moderately to severely active Crohn's disease (CD)
  3. CD involvement of the ileum and/or colon
  4. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents, within protocol-specified parameters:

    1. Immunomodulators
    2. Tumor necrosis factor-alpha (TNFα) antagonists
  5. May be receiving a therapeutic dose of conventional therapies for irritable bowel disease (IBD) defined by the protocol

Exclusion criteria

Exclusion Criteria

  1. Evidence of abdominal abscess at the initial screening visit, other than a minimum of 10 aphthous ulcerations involving a minimum of 10 contiguous cm of intestine
  2. Extensive colonic resection, subtotal or total colectomy
  3. History of >3 small bowel resections or diagnosis of short bowel syndrome
  4. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
  5. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol
  6. Chronic or C infection
  7. Active or latent tuberculosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,116 participants (actual)

Study arms

  • Experimental
    Vedolizumab

    In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15). In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.

    Drug: vedolizumab

  • Placebo comparator
    Placebo

    In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.

    Other: Placebo

Interventions

  • Vedolizumab for intravenous infusion

    Also known as: Entyvio, MLN0002, MLN02, LDP-02

  • OtherPlacebo

    Placebo intravenous infusion

06

What researchers measure

Primary outcomes

  1. Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 6

  2. Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6

    Enhanced clinical response is defined as a CDAI score at least 100 points lower than Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.

    Time frame: Baseline and Week 6

  3. Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52

    Clinical remission is defined as a CDAI score ≤ 150. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 52

Secondary outcomes

  1. Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6

    C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. Higher levels indicate mild inflammation (10-40 mg/L) and active inflammation (40-200 mg/L).

    Time frame: Baseline and Week 6

  2. Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52

    Enhanced clinical response is defined as a CDAI score at least 100 points lower than the Baseline value. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.

    Time frame: Baseline and Week 52

  3. Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52

    Participants using oral corticosteroids at Baseline, who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 52 achieved corticosteroid-free clinical remission. The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free clinical remission.

    Time frame: Week 52

  4. Maintenance Phase: Percentage of Participants With Durable Clinical Remission

    Durable clinical remission is defined as CDAI score ≤ 150 points at 80% or more of study visits during the Maintenance Phase, including the Week 52 visit (11 of 13 study visits). The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission

    Time frame: Assessed every 4 weeks from Week 6 to Week 50, and at Week 52

07

Results

Posted Jul 21, 2014

Participant flow

Participants took part in the study at 285 investigative sites worldwide from 23 December 2008 to 08 May 2012. The Induction Phase contained 2 cohorts. The eligibility criteria for both cohorts were identical. The purpose of Cohort 2 was to provide enough responders to power the Maintenance Phase primary efficacy analysis.

Induction Phase
Participant flow — Induction Phase
MilestonePlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab Q8WMaintenance Phase: Vedolizumab Q4WMaintenance Phase: Non-Responders
Started1482207480000
Treated1482207470000
Completed1371996740000
Not completed1121740000
Withdrew: Adverse event79240000
Withdrew: Protocol violation0010000
Withdrew: Lack of efficacy13280000
Withdrew: Withdrawal by subject39160000
Withdrew: Lost to follow-up0030000
Withdrew: Other0020000
Maintenance Phase
Participant flow — Maintenance Phase
MilestonePlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab Q8WMaintenance Phase: Vedolizumab Q4WMaintenance Phase: Non-Responders
Started13700153154154412
Completed4200647382163
Not completed9500898172249
Withdrew: Adverse event7001512938
Withdrew: Protocol violation0001234
Withdrew: Lack of efficacy7900645848177
Withdrew: Withdrawal by subject70076924
Withdrew: Lost to follow-up2001325
Withdrew: Other0001011

Outcome measures

PrimaryInduction Phase: Percentage of Participants Achieving Clinical Remission at Week 6

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6
percentage of participantsPlaceboDB Vedolizumab
Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 66.8 (2.7 to 10.8)14.5 (9.9 to 19.2)
Statistical analysis
  • Placebo vs DB Vedolizumab · Cochran-Mantel-Haenszel · p = 0.0206 (P-value is based on the Cochran-Mantel-Haenszel (CMH) chi-square test, with stratification according to: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no).) · Risk difference (rd): 7.8 · 95% CI 1.2 to 14.3Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
PrimaryInduction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6

Enhanced clinical response is defined as a CDAI score at least 100 points lower than Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.

Time frame:
Baseline and Week 6
Reported as:
Number · percentage of participants
Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6
percentage of participantsPlaceboDB Vedolizumab
Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 625.7 (18.6 to 32.7)31.4 (25.2 to 37.5)
Statistical analysis
  • Placebo vs DB Vedolizumab · Cochran-Mantel-Haenszel · p = 0.2322 (P-value is based on the Cochran-Mantel-Haenszel (CMH) chi-square test, with stratification according to: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no).) · Risk difference (rd): 5.7 · 95% CI -3.6 to 15.0Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
PrimaryMaintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52

Clinical remission is defined as a CDAI score ≤ 150. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 5221.6 (15.1 to 28.1)39.0 (31.3 to 46.7)36.4 (28.8 to 44.0)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = 0.0007 (CMH chi-square test, stratified by: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 3) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 17.4 · 95% CI 7.3 to 27.5Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = 0.0042 (CMH chi-square test, stratified by: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 3) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 14.7 · 95% CI 4.6 to 24.7Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
SecondaryInduction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6

C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. Higher levels indicate mild inflammation (10-40 mg/L) and active inflammation (40-200 mg/L).

Time frame:
Baseline and Week 6
Reported as:
Median · mg/L
Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6
mg/LPlaceboDB Vedolizumab
Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6-0.5 (-27.6 to 12.1)-0.9 (-20.6 to 10.3)
Statistical analysis
  • Placebo vs DB Vedolizumab · Wilcoxon (Mann-Whitney) · p = 0.9288 (Wilcoxon Rank Sum test on the CRP change from baseline values (two-sided).)
SecondaryMaintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52

Enhanced clinical response is defined as a CDAI score at least 100 points lower than the Baseline value. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 5230.1 (22.8 to 37.3)43.5 (35.7 to 51.3)45.5 (37.6 to 53.3)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = 0.0132 (CMH chi-square test, stratified by: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 3) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 13.4 · 95% CI 2.8 to 24.0Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = 0.0053 (CMH chi-square test, stratified by: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 3) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 15.3 · 95% CI 4.6 to 26.0Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
SecondaryMaintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52

Participants using oral corticosteroids at Baseline, who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 52 achieved corticosteroid-free clinical remission. The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free clinical remission.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 5215.9 (7.9 to 23.8)31.7 (21.6 to 41.8)28.8 (18.8 to 38.7)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = 0.0154 (P-value is based on the CMH chi-square test, with stratification according to: 1) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 2) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 15.9 · 95% CI 3.0 to 28.7Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = 0.0450 (P-value is based on the CMH chi-square test, with stratification according to: 1) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 2) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 12.9 · 95% CI 0.3 to 25.5Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
SecondaryMaintenance Phase: Percentage of Participants With Durable Clinical Remission

Durable clinical remission is defined as CDAI score ≤ 150 points at 80% or more of study visits during the Maintenance Phase, including the Week 52 visit (11 of 13 study visits). The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission

Time frame:
Assessed every 4 weeks from Week 6 to Week 50, and at Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Durable Clinical Remission
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants With Durable Clinical Remission14.4 (8.8 to 19.9)21.4 (14.9 to 27.9)16.2 (10.4 to 22.1)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = 0.1036 (CMH chi-square test, stratified by: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 3) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 7.2 · 95% CI -1.5 to 16.0Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = 0.6413 (CMH chi-square test, stratified by: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no); 3) enrollment in Cohort 1 or Cohort 2 in the Induction Phase.) · Risk difference (rd): 2.0 · 95% CI -6.3 to 10.2Risk Difference = adjusted (for stratification factors) percent vedolizumab - adjusted percent placebo

Adverse events

Collected over From the start of the Induction Phase until a final on-study safety assessment at Week 66 (or Final Safety visit 16 weeks after the last dose).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—23/148 (15.5%)96/148 (64.9%)
VDZ/PBO—23/153 (15%)96/153 (62.7%)
VDZ/VDZ—199/814 (24.4%)476/814 (58.5%)
Most frequent serious events
Showing 10 of 141
Most frequent serious events
EventPlaceboVDZ/PBOVDZ/VDZ
Crohn's diseaseGastrointestinal disorders13/1488/15399/814
Anal abscessInfections and infestations1/1480/15316/814
Abdominal painGastrointestinal disorders1/1482/1533/814
Ileal stenosisGastrointestinal disorders0/1482/1532/814
Abdominal abscessInfections and infestations0/1482/1535/814
Small intestinal obstructionGastrointestinal disorders1/1481/1536/814
Intestinal obstructionGastrointestinal disorders1/1480/1534/814
Anal fistulaGastrointestinal disorders1/1480/1531/814
Anal fissureGastrointestinal disorders1/1480/1530/814
Lower gastrointestinal haemorrhageGastrointestinal disorders1/1480/1530/814
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboVDZ/PBOVDZ/VDZ
Crohn's diseaseGastrointestinal disorders28/14823/15384/814
HeadacheNervous system disorders19/14828/15397/814
PyrexiaGeneral disorders17/14822/153102/814
Abdominal painGastrointestinal disorders21/14818/15379/814
ArthralgiaMusculoskeletal and connective tissue disorders19/14821/153110/814
NasopharyngitisInfections and infestations10/14814/153100/814
NauseaGastrointestinal disorders12/14818/15388/814
VomitingGastrointestinal disorders10/14813/15348/814
DiarrhoeaGastrointestinal disorders5/14812/15331/814
Upper respiratory tract infectionInfections and infestations11/1485/15354/814

Baseline characteristics

The Induction Phase Safety Population, defined as all participants, in both Cohort 1 and Cohort 2, who received any amount of study drug in the Induction Phase (Weeks 0 to 6), according to the actual study drug received.

Age, Continuous
Age, Continuous(years)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Mean38.6 ± 13.1636.3 ± 11.5735.6 ± 12.0136.1 ± 12.12
Age, Customized
Age, Customized(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
< 35 years67111404582
≥ 35 years81109343533
Age, Customized
Age, Customized(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
< 65 years1422187321092
≥ 65 years621523
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Female79115401595
Male69105346520
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Hispanic or Latino521926
Not Hispanic or Latino1392147121065
Unknown or Not Reported441624
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
White124182689995
Black331723
Asian19353589
Other2068
Region of Enrollment
Region of Enrollment(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Australia5103045
Austria43714
Belgium12174170
Bulgaria57214
Canada2212103137
Czech Republic11165380
Denmark02810
Estonia1236
France433744
Germany014950
Greece0022
Hong Kong2002
Hungary9174773
Iceland0044
India1019534
Ireland0022
Israel241218
Italy101314
Korea, Republic of3121126
Latvia0202
Malaysia1359
Netherlands0077
New Zealand45312
Norway001313
Poland761427
Romania0145
Russian Federation491528
Serbia0033
Singapore1001
Slovakia351018
South Africa331420
Spain1067
Sweden0189
Switzerland01910
Taiwan0033
Turkey2316
Ukraine34916
United Kingdom0066
United States2852188268
Body Weight
Body Weight(kg)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Mean68.7 ± 18.9067.1 ± 19.0770.8 ± 19.5669.8 ± 19.42

16 further baseline measures are reported on the registry.

08

Study locations

114 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Apex Clinical Trials
    Birmingham, Alabama 35234, United States
  • Gastrointestinal Bioscience
    Los Angeles, California 90067, United States
  • Paramount Medical Specialty
    Montebello, California 90640, United States
  • Capital Gastroenterology Consultants Medical Group
    Sacramento, California 95815, United States
  • Clinical Applications Laboratories Inc.
    San Diego, California 92103, United States
  • Desta Digestive Disease Medical Center
    San Diego, California 92114, United States
  • University of Colorado Health Sciences Center
    Aurora, Colorado 80045, United States
  • Rocky Mountain Clinical Research, LLC
    Golden, Colorado 80401, United States
  • Gastroenterology of the Rockies
    Lafayette, Colorado 80026, United States
  • Arapahoe Gastroenterology Associates P.C.
    Littleton, Colorado 80120, United States
  • South Denver Gastroenterology
    Lone Tree, Colorado 80124, United States
  • Lynn Institute of Pueblo
    Pueblo, Colorado 81007, United States
  • Connecticut Gastroenterology Institute
    Bristol, Connecticut 06010, United States
  • Gastroenterology Center of Connecticut, P.C.
    Hamden, Connecticut 06518, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • University of Florida, Jacksonville
    Jacksonville, Florida 32209, United States
  • East Coast Institute for Research
    Jacksonville, Florida 32223, United States
  • Borland-Groover Clinic
    Jacksonville, Florida 32256, United States
  • Center for Advanced Gastroenterology
    Maitland, Florida 32751, United States
  • Osler Clinical Research
    Melbourne, Florida 32901, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • United Medical Research Institute
    New Smyrna Beach, Florida 32168, United States
  • Compass Research LLC
    Orlando, Florida 32806, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • West Wind'r Research & Development, LLC
    Tampa, Florida 33607, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Southeast Regional Research Group
    Columbus, Georgia 31904, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Digestive Research Associates
    Newnan, Georgia 30263, United States
  • St. Joseph's/Candler Health System
    Savannah, Georgia 31405, United States
  • DLW Research System
    Snellville, Georgia 30039, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Carle Clinic Association P.C.
    Urbana, Illinois 58150, United States
  • Indianapolis Gastroenterology & Hepatology, Inc.- ARC
    Indianapolis, Indiana 46237, United States
  • Digestive & Liver Consultants
    Clive, Iowa 50325, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • University Of Kansas
    Kansas City, Kansas 66160, United States
  • Cotton O'Neil Digestive Health Center
    Topeka, Kansas 66606, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Gastroenterology Associates
    Baton Rouge, Louisiana 70809, United States
  • Metropolitan Gastroenterology Group, P.C.
    Chevy Chase, Maryland 20815, United States
  • Shah Associates
    Prince Frederick, Maryland 20678, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • The Center for Clinical Studies
    Dearborn, Michigan 48124, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
  • Minnesota Gastroenterology, P.A.
    Plymouth, Minnesota 55486, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Digestive Health Specialists
    Tupelo, Mississippi 38801, United States
  • Truman Medical Center
    Kansas City, Missouri 64108, United States
  • Center for Digestive and Liver Diseases, Inc.
    Mexico, Missouri 65265, United States
  • Washington University
    St. Louis, Missouri 63110, United States
  • St. Louis Center for Clinical Research
    St. Louis, Missouri 63128, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Affiliates in Gastroenterology PA
    Morristown, New Jersey 07960, United States
  • University of Medicine and Dentistry of New Jersey-NJMS
    New Brunswick, New Jersey 08903, United States
  • The Gastroenterology Group of South Jersey
    Vineland, New Jersey 08360, United States
  • Hepatobiliary Associates of New York
    Bayside, New York 11358, United States
  • Digestive Health Physician
    Cheektowaga, New York 14225, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Long Island Gastroenterology Group, P.C.
    Merrick, New York 11566, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Present Chapman Marion Steinlauf MD PC
    New York, New York 10028, United States
  • Kim, Chung MD (Private Practice)
    Pittsford, New York 14534, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Long Island Digestive Disease Consultants
    Setauket, New York 11733, United States
  • SUNY Stony Brook University Medical Center
    Stonybrook, New York 11794, United States
  • Syracuse Gastroenterological Associates
    Syracuse, New York 13210, United States
  • Asheville Gastroenterology Associates, P.A.
    Asheville, North Carolina 28801, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroentology and Hepatology, P.L.L.C
    Charlotte, North Carolina 28207, United States
  • Northwest Piedmont Clinical Research, Inc.
    Elkin, North Carolina 28621, United States
  • Burke Research Associates
    Morganton, North Carolina 28655, United States
  • Wake Forest University Baptist Medical Center
    Winston Salem, North Carolina 27157, United States
  • Consultants for Clinical Research Inc.
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Dayton Science Institute
    Dayton, Ohio 45415, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • The Oregon Clinic-West Hills Gastroenterology
    Portland, Oregon 97225, United States
  • University of Pittsburgh Medical Center - Cancer Centers
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University Of SC CAR
    Charleston, South Carolina 29425, United States
  • Consultants in Gastroenterology
    Columbia, South Carolina 29203, United States
  • Gastroenterology Center of the MidSouth, PC
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Austin Gastroenterology, PA
    Austin, Texas 78705, United States
  • Bayou City Research, Ltd.
    Houston, Texas 77024, United States
  • Gastroenterology Consultants
    Houston, Texas 77034, United States
  • Jacon Medical Research Associates
    Houston, Texas 77090, United States
  • Digestive Health Center
    Pasadena, Texas 77504, United States
  • Alamo Medical Research
    San Antonio, Texas 78215, United States
  • Gastroenterology Clinic of San Antonio
    San Antonio, Texas 78229, United States
  • Stone Oak Research Foundation
    San Antonio, Texas 78258, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States

Showing the first 100 of 114 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wyant T, Yang L, Rosario M. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials. AAPS J. 2020 Nov 16;23(1):3. doi: 10.1208/s12248-020-00518-0. PubMed 33200296 ↗
  • Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10. PubMed 32635680 ↗
  • Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019 Jul 17;25(8):1375-1382. doi: 10.1093/ibd/izy384. PubMed 30615117 ↗
  • Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125. PubMed 30203005 ↗
  • Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. doi: 10.1016/j.cgh.2018.05.026. Epub 2018 May 29. Erratum In: Clin Gastroenterol Hepatol. 2020 Mar;18(3):759. doi: 10.1016/j.cgh.2020.01.013. PubMed 29857145 ↗
  • Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27;12(5):621-626. doi: 10.1093/ecco-jcc/jjy019. PubMed 29471381 ↗
  • Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18. PubMed 26893500 ↗
  • Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20. Erratum In: Aliment Pharmacol Ther. 2015 Nov;42(9):1135. doi: 10.1111/apt.13365. PubMed 25996351 ↗
  • Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. PubMed 23964933 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Mar 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 2 years 4 months after primary completion. A results delay was requested in Apr 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2008
First posted
Nov 2, 2008
Start
Dec 2008
Primary completionActual
Mar 2012
CompletionActual
May 2012
Results delay requested
Apr 8, 2013
Results first posted
Jul 21, 2014
Last update
Jul 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00783692
Responsible party
Sponsor
First posted
Nov 2, 2008
Start date
Dec 2008
Primary completion
Mar 2012
Completion
May 2012
Results posted
Jul 21, 2014
Last update
Jul 21, 2014

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion